Nicole Onetto

Nicole Onetto, M.D., has been a member of the Board since 2017. She is also a member of the Corporate Governance Committee.

Ms. Onetto is an independent consultant in oncology, drug development and translational research. She was deputy director & chief scientific officer at the Ontario Institute for Cancer Research from 2009 to 2016. From 2005 to 2009 she was senior vice president and chief medical officer at ZymoGenetics Inc. From 2002 to 2005, she served at OSI Pharmaceuticals, Inc., first as executive vice president Oncology, and then as chief medical officer and executive vice president. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc.

Ms. Onetto is a member of the board of NBE Therapeutics AG and a member of the board of Sunesis Pharmaceuticals, Inc. She served as a board member of Sierra Oncology, Inc. from 2015 to November 2019 and as a board member of ImmunoGen Inc from 2005 to 2016.

Ms. Onetto holds a doctor of medicine from the University of Paris and a master of pharmacology from the University of Montréal.